Literature DB >> 29658927

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma.

Archana Vijaya Kumar1, Carmen Donate2, Beat A Imhof3, Thomas Matthes4.   

Abstract

B lymphocytes are key players in immune cell circulation and they mainly home to and reside in lymphoid organs. While normal B cells only proliferate when stimulated by T lymphocytes, oncogenic B cells survive and expand autonomously in undefined organ niches. Mantle cell lymphoma (MCL) is one such B cell disorder, where the median survival rate of patients is 4 - 5 years. This calls for the need of effective mechanisms by which the homing and engraftment of these cells are blocked in order to increase the survival and longevity of patients. Therefore, the effort to develop a xenograft mouse model to study the efficacy of MCL therapeutics by blocking the homing mechanism in vivo is of utmost importance. Development of animal recipients for human cell xenotransplantation to test early stage drugs have long been pursued, as relevant preclinical mouse models are crucial to screen new therapeutic agents. This animal model is developed to avoid human graft rejection and to establish a model for human diseases, and it may be an extremely useful tool to study disease progression of different lymphoma types and to perform preclinical testing of candidate drugs for hematologic malignancies, like MCL. We established a xenograft mouse model that will serve as an excellent resource to study and develop novel therapeutic approaches for MCL.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29658927      PMCID: PMC5933280          DOI: 10.3791/56023

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  13 in total

1.  Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Authors:  P Martin; A Chadburn; P Christos; R Furman; J Ruan; M A Joyce; E Fusco; P Glynn; R Elstrom; R Niesvizky; E J Feldman; T B Shore; M W Schuster; S Ely; D M Knowles; S Chen-Kiang; M Coleman; J P Leonard
Journal:  Ann Oncol       Date:  2008-03-17       Impact factor: 32.976

Review 2.  Chemokines and leukocyte traffic.

Authors:  M Baggiolini
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

3.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

Authors:  Jeffery M Klco; David H Spencer; Christopher A Miller; Malachi Griffith; Tamara L Lamprecht; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; Robert S Fulton; William C Eades; Daniel C Link; Timothy A Graubert; Matthew J Walter; Elaine R Mardis; John F Dipersio; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-06       Impact factor: 31.743

Review 4.  Human chemokines: an update.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  Dynamics of B cells in germinal centres.

Authors:  Nilushi S De Silva; Ulf Klein
Journal:  Nat Rev Immunol       Date:  2015-02-06       Impact factor: 53.106

6.  Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts.

Authors:  C C Scholz; D P Berger; B R Winterhalter; H Henss; H H Fiebig
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

Review 7.  Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.

Authors:  Robert S Kerbel
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

8.  Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma.

Authors:  Carmen Doñate; Archana Vijaya Kumar; Beat A Imhof; Thomas Matthes
Journal:  J Leukoc Biol       Date:  2016-06-02       Impact factor: 4.962

9.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

10.  Characteristics of human primary mantle cell lymphoma engraftment in NSG mice.

Authors:  Sunil Iyengar; Linda Ariza-McNaughton; Andrew Clear; David Taussig; Rebecca Auer; Amy Roe; Debra Lillington; Sameena Iqbal; Simon Joel; John Gribben; Dominique Bonnet
Journal:  Br J Haematol       Date:  2015-07-28       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.